Vaccine and anti-viral drug development for SARS-CoV2
Submission Deadline: 31 May 2022
Guest Editor
Laboratory of Influenza Research, College of Veterinary Medicine, Chungnam National University, Yuseong Gu, Daejeon, Republic of Korea
Interests: vaccine; epidemiology; pathogenicity on influenza virus and SARS-CoV-2
Special Issue in IMR Press journals
Special Issue in Research on Influenza Viruses
Special Issue Information
Dear Colleagues，
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) known as covid-19 still causes tremendous burden on humans. This virus has many variants such as Alpha, Beta, Gamma and Delta. Some variants have the potential for the increased trasnsmissibility, increased virulence, or reduced effectiveness of vaccines against current vaccines.
We need to develop better vaccine for protecting people from being infected from emerging variants SARS-CoV2 and anti-viral drugs to treat humans infected with SARS-CoV2. The goal of this special issue is to publish new approach to vaccines and anti-viral drugs for SARS-CoV2. Interesting researchers are encouraged to submit short reports, and full papers based on animal studies and human clinical trials.
Prof. Sang Heui Seo
Guest Editor
Published Papers (10)
Comparison of the Pathogenicity of SARS-CoV-2 Delta and Omicron Variants by Analyzing the Expression Patterns of Immune Response Genes in K18-hACE2 Transgenic Mice
Front. Biosci. (Landmark Ed) 2022, 27(11), 316; https://doi.org/10.31083/j.fbl2711316
(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)
Aptamer-Mediated Antiviral Approaches for SARS-CoV-2
Front. Biosci. (Landmark Ed) 2022, 27(11), 306; https://doi.org/10.31083/j.fbl2711306
(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)
Combination Therapies against COVID-19
Front. Biosci. (Landmark Ed) 2022, 27(9), 257; https://doi.org/10.31083/j.fbl2709257
(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)
Ginseng Protects ACE2-Transgenic Mice from SARS-CoV-2 Infection
Front. Biosci. (Landmark Ed) 2022, 27(6), 180; https://doi.org/10.31083/j.fbl2706180
(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)
The Potential Roles of BCG Vaccine in the Prevention or Treatment of COVID-19
Front. Biosci. (Landmark Ed) 2022, 27(5), 157; https://doi.org/10.31083/j.fbl2705157
(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)
Potential SARS-CoV-2 nonstructural proteins inhibitors: drugs repurposing with drug-target networks and deep learning
Front. Biosci. (Landmark Ed) 2022, 27(4), 113; https://doi.org/10.31083/j.fbl2704113
(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)
Variants of SARS CoV-2: mutations, transmissibility, virulence, drug resistance, and antibody/vaccine sensitivity
Front. Biosci. (Landmark Ed) 2022, 27(2), 65; https://doi.org/10.31083/j.fbl2702065
(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)
Thymosin-α1 binds with ACE and downregulates the expression of ACE2 in human respiratory epithelia
Front. Biosci. (Landmark Ed) 2022, 27(2), 48; https://doi.org/10.31083/j.fbl2702048
(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)
UV-4B potently inhibits replication of multiple SARS-CoV-2 strains in clinically relevant human cell lines
Front. Biosci. (Landmark Ed) 2022, 27(1), 3; https://doi.org/10.31083/j.fbl2701003
(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)
Heterogeneity in susceptibility to hydroxychloroquine of SARS-CoV-2 isolates
Front. Biosci. (Landmark Ed) 2021, 26(12), 1493–1502; https://doi.org/10.52586/5043
(This article belongs to the Special Issue Vaccine and anti-viral drug development for SARS-CoV2)